Similar to menin inhibitors, SYK inhibitors are being examined in combination with FLT3-ITD inhibitors as well as venetoclax and azacitidine in patients with newly diagnosed AML with NPM1 and FLT3 mutations. Here, NPM1 is linked to acute myeloid leukemia.